Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer

Huang, Yang; Li, G.; Li, W.F.

doi:10.4238/2015.january.30.13

Cited by 17 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, some Chinese [27,32] and Norwegian [33] studies assessed the ERCC1-rs11615 polymorphism and CRC risk but found no significant correlations [34], in accordance with the findings of the present study. In contrast, another Asian study showed that the ERCC1-rs11615 genotype T/T contributed to an increased CRC risk compared to CC genotype, although the risk was only marginal [35].…”

Section: Polymorphisms and Cancer Risksupporting

confidence: 91%

“…As an example, the XRCC1-rs25487 A allele ranges from 0.11 in the African population to 0.37 in European population [25], hence possibly contributing to different levels of susceptibility to CRC across populations. While previous studies on XRCC1-rs25487 confirmed the association of increased risk for CRC in particular among East Asians and Arab ethnicity [26][27][28][29], two meta-analysis studies, consistent with our results, suggested no association of this SNP and risk of CRC [30,31]. Further large and well characterized studies, therefore, are needed to identify the association between the XRCC1-rs25487 polymorphism and CRC risk and how it varies in different populations.…”

Section: Polymorphisms and Cancer Risksupporting

confidence: 84%

See 1 more Smart Citation

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

Salimzadeh

Lindskog

Gustavsson

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Single nucleotide polymorphisms (SNPs) in DNA repair genes have a potential clinical value in predicting treatment outcomes. In the current study, we examined the association of SNPs in the genes XRCC1-rs25487, ERCC1-rs11615, ERCC2-rs238406, and ERCC2-rs13181 with colorectal cancer (CRC) risk, relapse-free survival (RFS), overall survival (OS), and toxicity during chemotherapy.Methods: SNPs were analysed in 590 CRC cases and 300 controls using TaqMan technology. The association of SNPs with CRC risk and toxicity during chemotherapy was analysed using Chi2 test. The Kaplan–Meier method and log-rank test was used to measure the effects of the SNPs on RFS and OS.Results: The CC genotype of ERCC2-rs238406 and the ERCC2-rs13181 C allele were associated with a significantly increased risk of CRC. The ERCC1-rs11615 genotype T/T was associated with stomatitis in adjuvant chemotherapy (p= 0.03). Also, more patients with the ERCC2-rs13181 C allele needed dose reduction compared to patients with the A/A genotype (p= 0.02). In first line chemotherapy, more patients with the ERCC1-rs11615 C allele suffered from nausea compared to those with the T/T genotype (p= 0.04) and eye reactions and thrombocytopenia were more common in patients with the ERCC2-rs13181 C allele compared to the A/A genotype (p= 0.006 and p= 0.004, respectively). ERCC2- rs238406 C/C was also associated with a higher frequency of thrombocytopenia (p= 0.03). A shorter 5-year OS was detected in stage I & II CRC patients with the ERCC2- rs238406 C allele (p= 0.02). However, there was no significant association between the SNPs and 5-year RFS.Conclusions: Both SNPs in ERCC2 were associated with risk of CRC as well as toxicity during first line treatment. In addition, ERCC2- rs238406 was linked to OS in early stage CRC. The ERCC1-rs11615 variant was associated with toxicity during adjuvant chemotherapy. The results add support to previous findings that SNPs in ERCC1 and ERCC2 have a prognostic and predictive value in clinical management of CRC.

show abstract

Section: Polymorphisms and Cancer Risksupporting

confidence: 91%

Section: Polymorphisms and Cancer Risksupporting

confidence: 84%

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

Salimzadeh

Lindskog

Gustavsson

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Some Chinese [24,29] and Norwegian [30] studies assessed the ERCC1-rs11615 polymorphism and CRC risk but found no significant correlations [31], in accordance with the findings of the present study. In contrast, a study of a Chinese population showed that the ERCC1-rs11615 genotype T/T contributed to a 1.9-fold increased CRC risk compared to CC genotype [32].…”

Section: Polymorphisms and Cancer Risksupporting

confidence: 91%

“…As an example, the XRCC1-rs25487 A allele ranges from 0.11 in the African population to 0.37 in European population [22], hence possibly contributing to different levels of susceptibility to CRC across populations. While previous studies on XRCC1-rs25487 confirmed the association of increased risk for CRC in particular among East Asians and Arab ethnicity [23][24][25][26], two meta-analysis studies, consistent with our results, suggested no association of this SNP and risk of CRC [27,28]. Further large and well characterized studies, therefore, are needed to identify the association between the XRCC1-rs25487 polymorphism and CRC risk and how it varies in different populations.…”

Section: Polymorphisms and Cancer Risksupporting

confidence: 84%

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

Salimzadeh

Lindskog

Gustavsson

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : Single nucleotide polymorphisms (SNPs) in DNA repair genes have a potential clinical value in predicting treatment outcomes. In the current study, we examined the association of SNPs in the genes XRCC1-rs25487, ERCC1-rs11615, ERCC2-rs238406, and ERCC2-rs13181 with colorectal cancer (CRC) risk, relapse-free survival (RFS), overall survival (OS), and toxicity during chemotherapy. Methods: SNPs were analysed in 590 CRC cases and 300 controls using TaqMan technology. The association of SNPs with CRC risk and toxicity during chemotherapy was analysed using Chi2 test. The Kaplan–Meier method and Log-rank test was used to measure the effects of the SNPs on RFS and OS. Results: The ERCC2-rs238406 A allele and the ERCC2-rs13181 C allele were associated with a significantly increased risk of CRC. The ERCC1-rs11615 genotype T/T was associated with stomatitis in adjuvant chemotherapy ( p = 0.03). Also, more patients with the ERCC2rs13181 C allele needed dose reduction compared to patients with the A/A genotype ( p = 0.02). In first line chemotherapy, more patients with the ERCC1-rs11615 C allele suffered from nausea compared with those with the T/T genotype ( p = 0.04) and eye reactions and thrombocytopenia were more common in patients with the ERCC2-rs13181 C allele compared to the A/A genotype ( p = 0.006 and p = 0.004, respectively). Also, ERCC2- rs238406 C/C was associated with a higher frequency of thrombocytopenia ( p =0.03). A shorter 5-year OS was detected in stage I & II CRC patients with the ERCC2- rs238406 C allele ( p = 0.02). However, there was no significant association between the SNPs and 5-year RFS. Conclusions: Both SNPs in ERCC2 were associated with risk of CRC as well as toxicity during first line treatment. In addition, ERCC2- rs238406 was linked to OS in early stage CRC. The ERCC1-rs11615 variant was associated with toxicity during adjuvant chemotherapy. The results add support to previous findings that SNPs in ERCC1 and ERCC2 have a prognostic and predictive value in clinical management of CRC.

show abstract

“…Recently, ERCC1 polymorphisms were found to be associated with colorectal cancer risk (Yang et al, 2015). In addition, expression of ERCC1 could predict the clinical outcomes of non-small cell lung cancer patients receiving platinum-based chemotherapy (Wang et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

Cai

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinumbased chemotherapy in patients with late-stage bladder cancer. A total of 41 eligible patients histologically confirmed as having stage IV muscleinvasive transitional cell carcinoma of the bladder were treated with platinum-based chemotherapy for 2-6 cycles. The genotypes of patients were determined by PCR amplification of genomic DNA followed by restriction enzyme digestion. Positive responses were categorized as complete and partial responses. In addition, progression-free survival (PFS) and overall survival (OS) were also determined as indicators of long-term outcomes. The genotype frequencies of C/C, C/T and T/T genotypes were 56.1, 34.1, and 9.8%, respectively. Positive response was observed in 14 patients (34.1%), while 27 patients (65.9%) were negative responders. As compared with individuals carrying the C/T and T/T genotypes, those with the C/C genotype had significantly improved short-term treatment responses (P = 0.018). The median PFS of patients carrying the C/C genotype was 6.3 months, while that of patients with C/T and T/T genotypes was 4.2 months (P = 0.023). Moreover, the median OS for patients carrying the C/C genotype was also longer as compared with that of patients carrying C/T and T/T (11.7 months vs 8.5 months, P = 0.040). Our results indicated that the ERCC1 codon 118 polymorphism may have predictive potential for chemotherapy treatment responses in late-stage bladder cancer patients.

show abstract

Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer

Cited by 17 publications

References 22 publications

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

Contact Info

Product

Resources

About